The EMCDDA has a comprehensive publications programme targeting a wide range of audiences, including EU, national and regional policymakers, scientists and academics, practitioners in the drugs field, the media and the general public.
Printed publications can be directly ordered from the EU Bookshop.
You can also subscribe to receive the publication series Annual report, Drugnet Europe and Drugs in focus in printed format regularly.
Please click on one of the options below to see a selection of publications or choose 'list all publications' to get a complete overview of all EMCDDA publications.
Annual report | Drugnet Europe | Drugs in focus | Insights | Joint publications | Literature reviews | Manuals | Monographs | National reports | Risk assessments | Selected issues | Technical data sheets | Thematic papers
2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996
policymakers | practitioners in the drugs field | scientists and researchers | general public
Annual accounts | Brochures | Budget | General report of activities | Work programmes
Responding to drug driving in Europe September 2009 This study underlines the need for enforceable and evidence-based laws in the area of drug driving.
Methamphetamine: a European Union perspective in the global context July 2009 This study focuses on the supply and use of methamphetamine in Europe, set in a global context.
Strategy and work programme 2010-2012 July 2009 This work programme ensures that the EMCDDA remains a key resource for Europe — providing high-quality information to underpin effective drug policies and serving as a catalyst for supporting and developing national information systems.
Drugs in focus 19: Neurobiological research on drugs June 2009 This briefing paper for policymakers presents how new discoveries in neurobiology have the potential to transform our perception of drug addiction and its treatment.
Monograph 9: Addiction neurobiology June 2009 This report reviews developments in the neuroscience of addiction, explores how they might affect the way we view and treat drug problems, and considers the issues that they raise for drug policy in Europe.